Literature DB >> 21409391

BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer.

Michelle W Wong1, Cecilia Nordfors, David Mossman, Gordana Pecenpetelovska, Kelly A Avery-Kiejda, Bente Talseth-Palmer, Nikola A Bowden, Rodney J Scott.   

Abstract

Mutations in the recognized breast cancer susceptibility genes BRCA1, BRCA2, TP53, ATM, and CHEK2 account for approximately 20% of hereditary breast cancer. This raises the possibility that mutations in other biologically relevant genes may be involved in genetic predisposition to breast cancer. In this study, BRIP1, PALB2, and RAD51C were sequenced for mutations as a result of previously being associated with breast cancer risk due to their role in the double-strand break repair pathway and their close association with BRCA1 and BRCA2. Two truncating mutations in PALB2 (Q66X and W1038X), one of which is has not been reported before, were detected in an independent Australian cohort of 70 individuals with breast or ovarian cancer, and have strong family histories of breast or breast/ovarian cancer. In addition, six missense variants predicted to be causative were detected, one in BRIP1 and five in PALB2. No causative variants were identified in RAD51C. This study supports recent observations that although rare, PALB2 mutations are present in a small but substantial proportion of inherited breast cancer cases, and indicates that RAD51C at a population level does not account for a substantial number of familial breast cancer cases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21409391     DOI: 10.1007/s10549-011-1443-0

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  40 in total

1.  Novel germline PALB2 truncating mutations in African American breast cancer patients.

Authors:  Yonglan Zheng; Jing Zhang; Qun Niu; Dezheng Huo; Olufunmilayo I Olopade
Journal:  Cancer       Date:  2011-08-26       Impact factor: 6.860

2.  Germline mutations in BRIP1 and PALB2 in Jewish high cancer risk families.

Authors:  Irene Catucci; Roni Milgrom; Anya Kushnir; Yael Laitman; Shani Paluch-Shimon; Sara Volorio; Filomena Ficarazzi; Loris Bernard; Paolo Radice; Eitan Friedman; Paolo Peterlongo
Journal:  Fam Cancer       Date:  2012-09       Impact factor: 2.375

3.  Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.

Authors:  Tom Walsh; Silvia Casadei; Ming K Lee; Christopher C Pennil; Alex S Nord; Anne M Thornton; Wendy Roeb; Kathy J Agnew; Sunday M Stray; Anneka Wickramanayake; Barbara Norquist; Kathryn P Pennington; Rochelle L Garcia; Mary-Claire King; Elizabeth M Swisher
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-17       Impact factor: 11.205

4.  Mutation screening of RAD51C in high-risk breast and ovarian cancer families.

Authors:  Wenping Lu; Xianshu Wang; Hongsheng Lin; Noralane M Lindor; Fergus J Couch
Journal:  Fam Cancer       Date:  2012-09       Impact factor: 2.375

5.  Distinct cellular phenotype linked to defective DNA interstrand crosslink repair and homologous recombination.

Authors:  Aleksandra M Gorniewska; Katarzyna Kluzek; Lidia Gackowska; Izabela Kubiszewska; Malgorzata Z Zdzienicka; Aneta Bialkowska
Journal:  Mol Med Rep       Date:  2017-06-15       Impact factor: 2.952

6.  Rare germline mutations in PALB2 and breast cancer risk: a population-based study.

Authors:  Marc Tischkowitz; Marinela Capanu; Nelly Sabbaghian; Lili Li; Xiaolin Liang; Maxime P Vallée; Sean V Tavtigian; Patrick Concannon; William D Foulkes; Leslie Bernstein; Jonine L Bernstein; Colin B Begg
Journal:  Hum Mutat       Date:  2012-02-15       Impact factor: 4.878

Review 7.  Pathogenesis, prevention, diagnosis and treatment of breast cancer.

Authors:  Rupen Shah; Kelly Rosso; S David Nathanson
Journal:  World J Clin Oncol       Date:  2014-08-10

8.  Development of a novel PTT assay for mutation detection in PALB2 large exons and PALB2 screening in medullary breast cancer.

Authors:  Nikoleta Poumpouridou; Nikolaos Goutas; Christina Tsionou; Kleanthi Dimas; Evi Lianidou; Christos Kroupis
Journal:  Fam Cancer       Date:  2016-04       Impact factor: 2.375

9.  Prevalence of PALB2 mutations in Australasian multiple-case breast cancer families.

Authors:  Zhi L Teo; Daniel J Park; Elena Provenzano; Catherine A Chatfield; Fabrice A Odefrey; Tu Nguyen-Dumont; James G Dowty; John L Hopper; Ingrid Winship; David E Goldgar; Melissa C Southey
Journal:  Breast Cancer Res       Date:  2013-02-28       Impact factor: 6.466

10.  The incidence of PALB2 c.3113G>A in women with a strong family history of breast and ovarian cancer attending familial cancer centres in Australia.

Authors:  Zhi L Teo; Sarah D Sawyer; Paul A James; Gillian Mitchell; Alison H Trainer; Geoffrey J Lindeman; Kylie Shackleton; Linda Cicciarelli; Melissa C Southey
Journal:  Fam Cancer       Date:  2013-12       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.